Express Scripts: HCV Formulary Could Change With Merck Combo's Approval
Executive Summary
Exclusive formulary position for AbbVie's Viekira Pak remains in place for 2016, but an approval of Merck's combo is expected to place further downward pressure on HCV drug prices, which could mean a broader formulary in 2017 and beyond.
You may also be interested in...
ImmunityBio Will Aim Anktiva At Large Share Of Bladder Cancer Market
Execs Richard Adcock and Patrick Soon-Shiong told Scrip the company sees an addressable US population of about 20,000 and is aiming for ease of physician adoption.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.